Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.
Byoung Chul ChoIrene BrañaBeatriz CirauquiSercan AksoyFelix CoutureRuey-Long HongWilson H MillerManuel Chaves-CondeMargarida TeixeiraLance LeopoldMihaela MunteanuJoy Yang GeRamona F SwabyBrett G M HughesPublished in: BMC cancer (2024)
NCT03358472. Date of trial registration: November 30, 2017.